scholarly journals Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients

2015 ◽  
Vol 34 (12) ◽  
pp. 723-737
Author(s):  
João Costa ◽  
Francesca Fiorentino ◽  
Daniel Caldeira ◽  
Mónica Inês ◽  
Catarina Lopes Pereira ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Vitamin K ◽  
Oral Anticoagulants ◽  
Vitamin K Antagonist ◽  
New Oral Anticoagulants

scholarly journals Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation

Medicine ◽  
2020 ◽  
Vol 99 (36) ◽  
pp. e22054
Author(s):  
Zojaina Hernández Rojas ◽  
Maria Rosa Dalmau Llorca ◽  
Carina Aguilar Martín ◽  
Alessandra Queiroga Gonçalves ◽  
Marc Casajuana ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Vitamin K ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Vitamin K Antagonist

scholarly journals Cost-Effectiveness Of The Non-Vitamin K Antagonist Oral Anticoagulants For Atrial Fibrillation In Portugal

2015 ◽  
Vol 18 (7) ◽  
pp. A393
Author(s):  
J Costa ◽  
F Fiorentino ◽  
D Caldeira ◽  
M Inês ◽  
C Pereira ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Vitamin K ◽  
Oral Anticoagulants ◽  
Vitamin K Antagonist

Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation

2020 ◽  
Vol 29 (3) ◽  
pp. 390-400 ◽  
Author(s):  
Piyameth Dilokthornsakul ◽  
Surakit Nathisuwan ◽  
Rungroj Krittayaphong ◽  
Aurauma Chutinet ◽  
Unchalee Permsuwan
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Vitamin K ◽  
Oral Anticoagulants ◽  
Cost Effectiveness Analysis ◽  
Vitamin K Antagonist ◽  
Effectiveness Analysis

scholarly journals The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis

2020 ◽  
Vol 18 (1) ◽  
pp. 137
Author(s):  
Kuang-Tsu Yang ◽  
Wei-Chih Sun ◽  
Tzung-Jiun Tsai ◽  
Feng-Woei Tsay ◽  
Wen-Chi Chen ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Gastrointestinal Bleeding ◽  
Vitamin K ◽  
Meta Analysis ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Vitamin K Antagonist ◽  
Cochrane Library ◽  
Secondary Outcome ◽  
Optimal Dosage

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used to prevent atrial fibrillation (AF) patients from thromboembolic events than vitamin K antagonists (VKAs). However, the gastrointestinal bleeding (GIB) risk in the Asian AF patients associated with NOACs in comparison with VKAs remained unaddressed. Materials and Methods: A systematic search of studies on NOACs and VKAs in the Asian AF patients was conducted in PubMed, Cochrane Library, and ClinicalTrials.gov. The primary outcome was the hazard ratio (HR) of any GIB associated with NOACs versus VKAs. The secondary outcome was the GIB risks in different kinds of NOACs compared with VKAs. Results: This meta-analysis included two randomized controlled trials (RCTs) and four retrospective studies, comprising at least 200,000 patients in total. A significantly lower HR of GIB risks was found in all kinds of NOACs than VKAs in the Asian AF patients (HR: 0.633; 95% confidence interval: 0.535–0.748; p < 0.001). Additionally, the GIB risks of different NOACs were apixaban (HR: 0.392), edoxaban (HR: 0.603), dabigatran (HR: 0.685), and rivaroxaban (HR: 0.794), respectively. Conclusions: NOACs significantly reduced the risk of GIB in the Asian AF patients compared with VKAs. In the four NOACs compared with VKAs, apixaban probably had a trend of the least GIB risk. We need further head-to-head studies of different NOACs to confirm which NOAC is the most suitable for Asian AF patients and to know the optimal dosage regimen of different NOACs.

Sign in / Sign up

Export Citation Format

Share Document